<DOC>
	<DOCNO>NCT00769041</DOCNO>
	<brief_summary>This study ass whether treatment therapeutic ( 100 mg ) supratherapeutic ( 800 mg ) dose avanafil potential cause QT/QTc prolongation healthy volunteer .</brief_summary>
	<brief_title>A Thorough EKG Safety Study TA-1790 ( Avanafil )</brief_title>
	<detailed_description />
	<mesh_term>Erectile Dysfunction</mesh_term>
	<mesh_term>Moxifloxacin</mesh_term>
	<mesh_term>Fluoroquinolones</mesh_term>
	<mesh_term>Norgestimate , ethinyl estradiol drug combination</mesh_term>
	<criteria>1 . Male ; 2 . Between 18 45 year age , inclusive ; 3 . Have BMI range 19 28 kg/m2 , inclusive ; 4 . Have clinically significant abnormal finding physical examination , ECG , blood pressure , HR , medical history , clinical laboratory result Screening ; 5 . Be willing able comply trial requirement ; 6 . Have give write informed consent . 1 . Subjects participate another clinical trial within last 30 day currently participate another trial investigational drug . 2 . Subjects participate previous clinical trial avanafil . 3 . Subjects know allergy hypersensitivity avanafil , sildenafil ( ViagraÂ® ) , vardenafil ( LevitraÂ® ) , tadalafil ( CialisÂ® ) component drug product ; moxifloxacin component ; quinolone antibiotic . 4 . Subjects experience doselimiting adverse effect therapy PDE5 5 . Subjects condition possibly affect drug absorption 6 . Subjects evidence history clinically significant allergic ( except untreated , asymptomatic , seasonal allergy time dose ) , hematological , endocrine , pulmonary , gastrointestinal , cardiovascular , hepatic , psychiatric , neurological disease . Exceptions criterion ( eg , stable , mild joint disease ) may make follow discussion Medical Monitor . 7 . Subjects medical history positive serology test human immunodeficiency virus ( HIV ) , hepatitis B virus surface antigen ( HBsAg ) , hepatitis C virus ( HCV ) . 8 . Subjects history drug alcohol abuse dependence within 18 month prior Screening . 9 . Subjects donate blood blood component within 4 week prior Period 1 Checkin . 10 . Subjects laboratory value outside normal range local laboratory . 11 . Subjects sustain supine SBP &gt; 140 mmHg &lt; 100 mm Hg DBP &gt; 95 mmHg Screening baseline . 12 . Subjects rest HR &lt; 45 bpm &gt; 100 bpm . 13 . Subjects abnormal Screening ECG indicate second thirddegree atrioventricular ( AV ) block , 1 following : QRS interval &gt; 110 msec , QTc interval &gt; 450 msec , PR interval &gt; 240 msec , rhythm sinus rhythm , interpret Investigator clinically significant . 14 . Subjects use use tobaccocontaining product within 6 month prior Period 1 Checkin throughout study . 15 . Subjects consume alcohol , caffeine , xanthinecontaining product within 72 hour prior Period 1 Checkin throughout study . 16 . Subjects test positive drug ( ) abuse , alcohol , cotinine Screening Checkin period . 17 . Subjects concomitant medication usage nitrate , trazadone , ketoconozole , erythromycin , cimetidine , androgen replacement therapy and/or use prescription overthecounter drug know interfere metabolism CYP3A4 . 18 . Subjects use drug may prolong QT/QTc interval within 30 day . 19 . Subjects use prescription drug overthecounter herbal medication within 14 day 20 . Subjects involve plan and/or conduct study . 21 . Subjects , reason , deem Investigator inappropriate study , include subject unable communicate cooperate Investigator .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>January 2011</verification_date>
</DOC>